Global leading language service provider
EN
CN EN

New Drug Launches: Timing Is Everything

R&D takes a decade, but launch is a race against time. We deeply integrate four core capabilities: multilingual clinical translation, international regulatory consulting, eCTD Integration, and global brand launch. This helps eliminate language barriers and compliance risks during the final sprint to market, ensuring that innovative drugs enter global markets as quickly as possible and in the strongest possible position.

Banner002731-icon1.svg

Dual US-China Submission

Meeting FDA and NMPA
Submission Requirements in Parallel

Banner002731-icon2.svg

Rapid eCTD Submission

100% First-Pass Rate in Technical Validation

Banner002731-icon3.svg

Commercial Launch

Comprehensive planning from
academic conferences to market access

Book a Launch Strategy Consultation View New Drug Launch Case Studies

  • Launch Pain Points

    The hidden traps of the "last mile."
    Companies often face three major challenges:

    Data deluge and consistency risks：Hundreds of thousands of pages of clinical study reports (CSRs) and chemistry, manufacturing, and controls (CMC) materials must be translated into multiple languages within an extremely short timeframe, while maintaining a high degree of terminology consistency with the earlier IND stage.

    Stringent regulatory technical barriers：Even a single XML tag error or broken hyperlink may cause an eCTD submission to be refused to file (RTF) by regulatory authorities, resulting in millions of dollars in losses due to launch delays.

    Commercial language disconnect：R&D language, which is rigorous and technical, cannot be directly converted into marketing language that engages target audiences, preventing newly launched drugs from quickly gaining recognition among physicians and patients.

  • Glyph Translation Strategy

    More than just translation, it is a "launch risk control system."
    Glyph Translation (Shenzhen) breaks away from the inefficient model of traditional fragmented outsourcing. We provide integrated, full-lifecycle solutions:

    Integration：Connecting the language assets of R&D, registration, and marketing to ensure zero loss in information flow.

    Proactive compliance：Bringing the compliance perspective of former reviewers into the translation stage to mitigate the risk of deficiency notices at the source.

    Technology-driven：Leveraging AI and DTP technologies to increase document processing efficiency by more than 50%, helping you reclaim valuable market exclusivity.

Core Pain Point

In multi-regional clinical trials (MRCT), data quality varies across research centers in different countries, and the language styles of source documents are fragmented, which easily leads to difficulties in pooled analysis.

Our Service Portfolio

Standardized Clinical Translation

Covered documents: Protocol, Investigator's Brochure (IB), Informed Consent Form (ICF), and Clinical Study Report (CSR).

Quality control: Utilizing MD/PhD-level medical experts for review to ensure accurate MedDRA terminology coding and full compliance with ICH-GCP standards.

Accelerated patient recruitment: Converting complex inclusion and exclusion criteria into clear, patient-friendly recruitment language to accelerate subject enrollment.

Clinical Data Services

Assisting in converting heterogeneous clinical source data into CDISC-compliant formats (SDTM/ADaM) to ensure data can be seamlessly read by FDA/NMPA systems.

Core Pain Point

The compilation and publishing of submission dossiers is the most technically demanding and high-risk stage. Formatting errors, broken links, and non-compliant PDF properties are the main causes of rejection.

Our Service Portfolio

eCTD Integration Publishing

Document engineering: Whether the source files are Word, PDF, or images, our DTP team can convert them into standard documents that meet granularity requirements.

Smart hyperlinks: Using proprietary plug-ins to automatically build tens of thousands of hyperlinks and bookmarks between documents, ensuring reviewers can trace sources with a single click.

Gateway submission: Generating validated XML backbone files and supporting direct submissions to the FDA and EMA via the ESG gateway.

Mock Audit & Response

Mock pre-review: Organizing senior registration experts to conduct a mock review of the full submission dossier and identify logical gaps in advance.
Response to Deficiency: Providing 24-hour urgent translation and editing support after receiving questions from regulatory authorities, and assisting in drafting highly professional, well-structured response letters.

Core Pain Point

Product approval is only the first step. How can package inserts be made compliant with local formatting regulations? How can packaging design align with local aesthetic preferences? How can patients truly understand the information provided?

Our Service Portfolio

Labeling & Packaging

Regulatory formatting: Strictly following national labeling regulations (e.g., US SPL format, EU QRD templates, and China's Order No. 24) to design package inserts, cartons, and labels.

Readability Testing: Conducting user readability testing among patient populations to optimize the wording of medication instructions.

Device & Software Localization

Providing localization services for the embedded software UI/GUI of companion diagnostic reagents or drug delivery devices, ensuring interfaces are free from garbled text and layout overflow and comply with the IEC 62304 software lifecycle standard.

Core Pain Point

In the early stages of a new drug launch, physician awareness is low, and there is a lack of authoritative academic endorsement. How can complex "clinical data" be transformed into compelling "therapeutic value"?

Our Service Portfolio

Launch Event Management

Planning new drug launch ceremonies with stunning audio-visual effects. We provide full simultaneous interpretation, bilingual hosting, and global multi-location live streaming support to maximize launch visibility.

Global KOL Engagement

Connecting with top global medical experts to plan and produce Expert Interviews, MOA Videos, and academic publications. We help tell the scientific story of your new drug through the voices of authoritative experts.

  • Floor003197-01.jpg

    The client needed to simultaneously submit NDA applications to the FDA and NMPA within 3 months, involving the bidirectional translation of 150,000 pages of materials and the production of dual-standard eCTDs. At the time, the client's internal registration team was severely understaffed.

    Glyph Translation Action

    Resource Allocation ： Formed a special task force of "50 medical translators + 5 registration experts + 10 DTP engineers."

    Process Innovation： Adopted a "Rolling Submission" model, where DTP and eCTD compilation were performed immediately after a module was translated, enabling parallel operations.

    Technical Breakthrough ： Resolved 300+ chart overflow issues caused by word count differences between Chinese and English formatting.

    Results

    Completed all submissions 2 weeks ahead of schedule.

    Accepted by the FDA and NMPA without deficiency notices.

    The client saved approximately 40% in external vendor communication costs (translation, registration, and DTP handled by a single provider).

  • “ "During the critical window of our innovative drug's push toward FDA approval, the Glyph Translation team demonstrated exceptional professionalism and execution capabilities. They were not just translating documents; they were using language to safeguard our clinical value. Approval without deficiency notices is the best testament to our collaboration."

    —— Vice President of Regulatory Affairs, a NASDAQ-listed biotechnology company
Global Consultation Hotline：400 680 7218
21st Floor, Building 19, Zhonghai Xin Innovation Industry City, Jihua Street, Longgang District, Shenzhen
Copyright © 2025 甲骨文翻译（深圳）有限公司 All Rights Reserved.ICP
Legal NoticeFriendshipLinkSitemap